Jiangsu Yifan Biotechnology Co., Ltd. Overview
Yifan Pharmaceutical is a mid-cap Chinese pharmaceutical group in transition from a commodity-API and drug-promotion business toward an innovation-led, internationalised specialty pharma company. Its anchor asset is Ryzneuta®/亿立舒 (efbemalenograstim alfa, F-627), a self-developed, non-PEGylated long-acting G-CSF. Ryzneuta is approved in 39 countries or regions including China, the US and the EU, and it is the only Chinese-originated long-acting G-CSF recommended in the NCCN hematopoietic growth factor guidelines.
Around this asset the company has assembled three further businesses:
-
A portfolio of exclusive and NRDL-listed traditional Chinese medicines (TCM), including Compound Huangdai tablets, which is on the WHO Essential Medicines List.
-
Niche injectable and oral chemical drugs, plus imported specialty products such as Xeloda® and Hyruan ONE®.
-
A legacy synthetic-biology and vitamin B5 (D-calcium pantothenate) franchise in which it holds a leading global share.
About 85% of revenue is drug-related. Overseas formulation revenue, licensing (Acrotech in the US) and a new in-licensing strategy (ACT001) form its growth narrative. Domestic volume-based procurement and TCM headwinds weigh on near-term growth.
Company's own description (FY2025 annual report abstract, translated)
During the reporting period the company was principally engaged in the research and development, production and sale of pharmaceutical products, active pharmaceutical ingredients (APIs) and polymer materials, and in drug-promotion services. Under the CSRC industry classification it belongs to pharmaceutical manufacturing. Its pharmaceutical products comprise biologics, chemical drugs and Chinese patent medicines. Its vitamin products are mainly vitamin B5 and pro-vitamin B5 (FY2025 annual report abstract, cnstock, 24 April 2026).
Management organises the drug business into four capability domains:
-
Large molecules (biologics), anchored by Ryzneuta.
-
Small molecules (chemical drugs), positioned around a "small, sharp, special, fast-to-revenue" niche strategy.
-
Chinese patent medicines (TCM): 108 approval numbers, including 14 exclusive NRDL products.
-
Synthetic biology: vitamin B5, pro-B5 and HMOs (human milk oligosaccharides).
Business and revenue model
| Revenue type | Description | Approx. weight (FY2025) |
|---|---|---|
| Own pharmaceutical products (including imported and exclusively distributed products) | Branded biologics, chemical drugs and TCM, sold through distributors to hospitals and retail, and abroad through partners and own registrations | 74.75% of revenue (RMB 3,837M) |
| Vitamins (B5 / pro-B5) | Mostly direct B2B sales to feed, pharma, food and cosmetic customers. About 70% is exported to Europe, the Americas and other markets. | 11.95% (RMB 613M) |
| Other pharma revenue (promotion services, third-party products, milestones) | Includes Ryzneuta sales milestones from domestic partners and residual CSO-type promotion revenue | Residual of the pharma total of RMB 4,358M, i.e. about RMB 521M |
| Polymer materials and other | PVB (including photovoltaic-grade), PBS biodegradables, other | About RMB 162M (derived residual) |
The licensing and milestone component matters at the margin. In China, Ryzneuta is commercialised with domestic partners: the company "recognised sales milestones" in 2024 from which more than RMB 500M of 2024 terminal net sales was inferred. In the US, Ryzneuta is out-licensed to Acrotech Biopharma, an Aurobindo subsidiary, under a supply-and-license model in which Evive manufactures and supplies and Acrotech commercialises.
Value-chain position and customers
The company is vertically integrated across the value chain:
-
API and biologic drug-substance manufacturing, including Beijing biologics drug substance and EU/US-GMP sterile fill lines.
-
Formulation.
-
Registration across more than 50 markets.
-
Commercial promotion through domestic medical-promotion teams and South-East Asia registration and sales teams.
Customer types:
-
Pharmaceutical distributors and hospital channels in China.
-
Retail pharmacy for OTC TCM.
-
Overseas licensees and distributors.
-
B2B buyers of vitamin B5 and polymers.
End-markets:
-
Oncology supportive care (chemotherapy-induced neutropenia).
-
Haematologic oncology (APL).
-
Orthopaedics (knee osteoarthritis).
-
Dermatology, paediatrics and respiratory (TCM).
-
Critical care injectables.
-
Animal feed and nutrition (vitamin B5).
-
Photovoltaic and laminated glass (PVB).
Independent characterisation
Yifan is best understood as three businesses with very different economics:
-
A single-asset innovative biologics franchise (Ryzneuta). High gross margin, globally registered, but still commercially early overseas. Management concedes it "has not yet contributed profit at scale" (FY2025 annual report abstract).
-
A cash-generative but policy-exposed domestic specialty-generics and TCM portfolio. Exposed to volume-based procurement (VBP), DRG/DIP payment reform and hospital-sales compression, which drove the H1 2026 decline.
-
A cyclical commodity vitamin B5 business. Global leadership, but price-taker economics. This segment caused the 2021 earnings collapse (vitamin B5 revenue -61% in 2021).
The investment case rests on whether (1) and new in-licensed or clinical assets (ACT001, F-652, N-3C01) can outgrow the erosion in (2) and the cyclicality of (3).
Strategy
Stated strategy (annual and interim reports)
- Medium- to long-term plan: "innovation + internationalisation" (创新、国际化). The company commits to a "long-termist, safe, controllable, sustainable development philosophy" (H1 2025 report).
2025 operating theme: "Meet the challenge, respond to the challenge, win the challenge" (迎战、应战、赢战).
"Big product" cluster strategy (set for 2024): - Overseas: 2 products above RMB 100M and 4 above RMB 50M.
-
Domestic: 9 products above RMB 100M and 9 above RMB 50M.
-
In-license 8–10 new products around Ryzneuta for APAC and emerging markets.
-
First synthetic-biology product ready for trial production by end-2024.
Globalisation model: "licensing partnerships plus own registrations" across more than 50 markets, with the stated aim of moving from "product going abroad" to "value going abroad", i.e. pricing power (company and press framing, 2025).
R&D focus: differentiated innovation concentrated on a few large-molecule assets (G-CSF, IL-22), plus biosimilars with "head-generic" potential.
FY2026 plan (FY2025 annual report)
-
Advance:
-
N-3C01 China–Australia Phase I;
-
F-652 healthy-volunteer PK and the China Phase II in aGVHD;
-
tracking of the F-652 US IIT;
-
human growth hormone clinical trials;
-
ACT001 clinical progress and risk control;
-
Compound Yinhua Jiedu supplementary studies per CDE.
-
-
Lay out at least one best-in-class (BIC)-potential frontier target.
-
Initiate one or two biosimilars with head-generic potential.
-
Adopt a "Quality and Return Dual Improvement" (质量回报双提升) action plan (board, 22 Apr 2026), in line with CSRC market-value-management guidance.
Initiatives in the last 24 months
| Date | Initiative | Type |
|---|---|---|
| 2024–2025 | Transfer of Ryzneuta US/EU MAH to Evive entities; first-time US supply (delayed by packaging issues) | Platform / supply chain |
| 2,025 | HMO portfolio (2'-FL FDA, 6'-SL self-GRAS); new Hangzhou synthetic-biology plant | New business launch |
| 2,025 | PIC/S inspection (norepinephrine); EU certification (amikacin) | International quality platform |
| 2,025 | Oxytocin nasal spray licensed to Sygardis Rus (Russia) | Out-licensing |
| Jan 2026 | ACT001 in-licence (RMB 100M upfront) | Business development |
| H1 2026 | New Ryzneuta commercial partnerships in France, Italy, Poland and Bangladesh; EMA approval of an additional overseas formulation site; shelf-life extensions | Commercial / supply |
| Apr 2026 | Quality and Return Dual Improvement plan; new remuneration system; FY2025 Sustainability Report | Governance / ESG |
| Sep 2026 | RMB 100M LP commitment to the Gaorong Changying fund (RMB 3.35bn target), focused on emerging industries | Strategic investment |
Guidance
The company does not issue formal numerical guidance. Its budget commentary for vitamins ("basically in line with the beginning-of-year budget target") and its product-count ambitions are the closest equivalents. No medium-term revenue or margin targets were found.
Products & Services
Prices are not disclosed unless stated. "NRDL" means China National Reimbursement Drug List.
Large molecules (biologics)
| Product | Description and capabilities | Target customer | Approval / launch | Commercial model / price |
|---|---|---|---|---|
| Ryzneuta® / 亿立舒 (efbemalenograstim alfa, F-627) | Novel dimeric G-CSF Fc-fusion protein; long-acting without PEGylation; prevention of chemotherapy-induced neutropenia. The only G-CSF with head-to-head trials against both the long-acting and short-acting originators that met pre-set endpoints. Included in NCCN HGF guidelines (Category 1 in v3.2026; v1.2025 inclusion), the CSCO breast cancer guideline 2025 and the German S3 supportive-therapy guideline. Shelf life is 36 months in China and 48 months overseas (EU/FDA approved). | Oncology centres; chemotherapy patients | China 2023 (first shipments Jun 2023); US FDA Nov 2023; EU Mar 2024; 39 countries or regions by mid-2026 | China: partner model with sales milestones; NRDL since Dec 2023 (with a later price cut noted in H1 2026). US: licensed to Acrotech; launched Jul 2025 at USD 4,600 per vial, about 14x the China price. Europe and other markets: partners in France, Italy, Poland, Bangladesh and others. |
| F-652 (recombinant human IL-22-Fc fusion protein) | First-in-class IL-22 agonist candidate | Hepatology and transplant | Clinical: China IND for ACLF (2021); China Phase II IND for acute GVHD (Jan 2026); higher-dose PK in healthy volunteers completed; US IIT ongoing | Pipeline |
| N-3C01 injection | Innovative biologic for advanced solid tumours and NMIBC | Oncology | IND cleared in 2025; China–Australia Phase I planned for 2026 | Pipeline |
| Insulin glargine injection; human growth hormone injection | Biosimilars / follow-on biologics | Endocrinology | Clinical trial approvals received in 2025 | Pipeline |
| Third-generation insulins (three products) | Biosimilars for overseas markets | Diabetes | Pre-clinical (2024) | Pipeline |
| F-899 | Innovative biologic; China IND completed 2021 | Not detailed | Clinical | Pipeline |
Small molecules: chemical drugs (domestic)
| Product | Description | Therapeutic area | Notes |
|---|---|---|---|
| Xeloda® (capecitabine tablets) | Oral fluoropyrimidine | Oncology | Imported or licensed brand; volume growth in 2025 |
| Hyruan ONE® / 易尼康 (cross-linked sodium hyaluronate injection) | Single-injection viscosupplement; LG Chem's Synovian | Knee osteoarthritis | Exclusive import and distribution; China approval Apr 2023; NRDL Dec 2023; H1 2025 shipments +478%; FY2025 sales +224.72% |
| Emedastine difumarate extended-release capsules | Antihistamine | Allergy / dermatology | 2025 volume growth |
| Puvanle® / 普帆乐 (plerixafor injection) | Stem-cell mobiliser | Haematology | — |
| Oxytocin nasal spray | Uterotonic / lactation | Obstetrics | Russia rights licensed to Sygardis Rus (2025) |
| Vincristine sulfate injection | Vinca alkaloid | Haemato-oncology | — |
| Norepinephrine bitartrate injection | Vasopressor | Critical care | PIC/S inspection passed; Singapore approval Feb 2026 |
| Phenylephrine hydrochloride injection | Vasopressor | Critical care | — |
| Yifala® / 亿法拉 (clofarabine injection) | Purine analogue | Paediatric ALL | — |
| Cytarabine for injection; epirubicin HCl for injection | Cytotoxics | Haemato-oncology | Registered H1 2025 |
| Vitamin K1 injection (0.2ml:2mg; 1ml:10mg) | Coagulation | Hospital | China approval Jan 2026 |
| Polymyxin B sulfate for injection | Last-line antibiotic | Infectious disease | China approval Jan 2026 |
| Lactulose oral solution | Laxative / hepatic encephalopathy | GI | Exclusive import or distribution |
| Amikacin sulfate injection | Aminoglycoside | Infectious disease | EU certified; shipped to Italy (2025) |
| Diazoxide oral suspension | Hyperinsulinism | Rare / paediatric | Emergency export to Brazil (2025) |
Small molecules: overseas
| Product | Market | Notes |
|---|---|---|
| Zometa® (zoledronic acid for injection) | Overseas, via the NovoTek / SciGen platform | Named overseas product (FY2025 annual report) |
| Imported and own formulations | South-East Asia, Singapore, EU (Italy) | Via SciGen (Singapore) and Italian subsidiaries |
Traditional Chinese medicines (108 approval numbers; 14 exclusive NRDL products)
| Product | Indication | Distinction |
|---|---|---|
| Baixuekang® / 柏雪康 (Compound Huangdai tablets, 复方黄黛片) | Acute promyelocytic leukaemia (APL) | Second-class National Science & Technology Progress Award; mechanism published in leading international journals including NEJM; in Chinese APL guidelines and the ELN consensus; on the WHO Essential Medicines List. Brazil APL study and a platinum-resistant ovarian cancer IIT under way. |
| Xiao'er Qingqiao granules (小儿青翘颗粒) | Paediatric respiratory | Exclusive NRDL product; sharp decline in H1 2026 |
| Compound Yinhua Jiedu granules (复方银花解毒颗粒) | Influenza / respiratory | Phase III in paediatric influenza completed and filed; CDE supplementary data requested |
| Chushi Zhiyang ointment (除湿止痒软膏) | Eczema / pruritus | Exported to Singapore (2025) |
| Pimingxiao capsules (皮敏消胶囊) | Dermatology / urticaria | Exported to Singapore; 2025 volume growth |
| Fuyinkang lotion (妇阴康洗剂) | Gynaecology | Exclusive |
| Maqin Xiaoke granules (麻芩消咳颗粒) | Cough | Singapore registration (second TCM registered overseas) |
| Ginkgo leaf pills (银杏叶丸) | Cardio-cerebrovascular | Exported to Singapore |
| Yihuang decoction granules (易黄汤颗粒) | Classical formula | NDA accepted Jan 2026 (Suzhou Yifan) |
| Duanjin Jiedu capsules (断金戒毒胶囊) | Opioid-dependence relapse prevention | Class 1.1 innovative TCM; Phase Ib completed (2025) |
Synthetic biology and vitamins
| Product | Description | Market position |
|---|---|---|
| Vitamin B5 (D-calcium pantothenate) and pro-vitamin B5 (D-panthenol) | Feed, pharma, food and cosmetic ingredients; direct sales; about 70% exported | Global leader by share; prices cyclical. Management cites industry oversupply in 2025. |
| HMOs: 2'-fucosyllactose (2'-FL) and 6'-sialyllactose (6'-SL) | Infant-formula and nutrition ingredients | FDA (GRAS) clearance for 2'-FL and self-GRAS for 6'-SL (2025); new Hangzhou plant ramping up |
Polymer materials
| Product | Description |
|---|---|
| Xinfu PVB resin and film | Including photovoltaic-grade PVB interlayer resin (investor-relations disclosure) |
| PBS fully biodegradable resin | Capacity of 10,000 t (investor-relations reply, Jul 2020; current capacity not re-verified) |
In-licensed pipeline
| Asset | Licensor | Terms | Status |
|---|---|---|---|
| ACT001 (dimethylaminomicheliolide fumarate monohydrate) | Tianjin Shangde Yaoyuan Technology and two subsidiaries | Exclusive, sublicensable rights for SCLC brain metastases in mainland China, Korea and several South-East Asian countries. RMB 100M upfront; cornerstone equity investment or milestones (alternative); tiered royalties on net sales. | NMPA Breakthrough Therapy designation (Jan 2025). Phase III: 166 patients enrolled in H1 2026, 76% of target. |
Financial Narrative
Basis and sources. All figures are PRC GAAP (CAS), consolidated, in RMB M, from audited annual reports:
-
FY2025: annual report abstract and cfi.cn.
-
FY2022–FY2024: FY2024 annual report key data.
-
FY2021: CS.com.cn summary of the FY2021 annual report.
Blank cells mean the figure was not disclosed in the sources reviewed. Computed ratios are marked (c).
Income statement
Notes:
-
FY2021 gross profit is computed (c) from the 41.47% gross margin.
-
FY2025 consolidated net profit is RMB 373.45M (Pharnexcloud). cfi.cn shows RMB 431.75M against minorities of RMB -28.57M, which is internally inconsistent (402.02 - 28.57 = 373.45). The RMB 373.45M figure is adopted.
-
Minorities are derived (c) as consolidated NP less attributable NP. Losses at Evive, 66.92% owned, explain the large FY2023 minority loss.
-
Dividends: FY2024 had an RMB 0.10 interim plus an RMB 0.10 final. Cumulative cash dividends for FY2023–FY2025 were RMB 364.9M, consistent with three payments of RMB 121.6M (FY2025 profit-distribution notice). The FY2021 dividend was nil (FY2021 annual report).
-
EBITDA: D&A was not captured in the sources reviewed, so EBITDA is not publicly disclosed here.
Margins and growth (%)
Revenue CAGR (c).
-
FY2021–FY2025: 3.9% per year (RMB 4,409M to RMB 5,133M).
-
FY2022–FY2025: 10.2% per year.
-
FY2020–FY2025: -1.0% per year, from the cyclical peak of RMB 5,401M.
Balance sheet
Notes:
-
FY2021 total assets and liabilities are computed (c) from RMB 8,535M of net assets and a 27.87% debt ratio.
-
FY2023 and FY2024 liabilities are computed (c) from the debt ratios reported by Radar Finance.
-
Cash and cash equivalents at year end were RMB 663.8M (FY2025), RMB 730.3M (Q1 2026) and RMB 809.5M (H1 2026) (cfi.cn).
-
Goodwill: the large FY2023 impairment reduced the FY2021 balance of RMB 2,738M (32% of net assets). The current balance is not captured.
-
Short-term and long-term borrowings, net debt and working capital are not captured in the sources reviewed (not publicly disclosed here). Contextual signals:
-
Stockstar notes cash covered only 33.63% of current liabilities at 3Q25.
-
The controlling shareholder personally guarantees up to RMB 3.0bn of bank borrowings.
-
Intra-group guarantees of up to RMB 6.0bn are authorised, equal to 67.92% of FY2025 net assets.
-
Cash flow
Capex and buybacks were not captured, so free cash flow is not publicly disclosed here. As a proxy, OCF plus investing cash flow was RMB +4M in FY2025. The company holds about 9.63M treasury shares from earlier buybacks. In H1 2026, OCF of RMB 593.5M was stronger than in H1 2025 (RMB 286.1M) on lower purchases and taxes and the timing of government grants.
Return and efficiency ratios
FY2025 ROE, ROA and asset turnover are computed (c). The following ratios are not publicly disclosed in the sources reviewed:
-
current ratio;
-
debt/equity (interest-bearing);
-
net debt/EBITDA;
-
interest coverage;
-
cash conversion cycle.
Liabilities/equity (total, not interest-bearing) was 0.47x in FY2025 (c).
Commentary on trends, inflections and drivers
FY2020–FY2021: commodity-cycle collapse. FY2020 was flattered by unusually high vitamin B5 prices. In FY2021, vitamin B5 revenue fell 61% to RMB 470M, API-segment gross margin fell by about 32 points, and promotion-service revenue fell 43% as partner products entered VBP. Group revenue fell 18% and attributable NP fell 71%. Management's response was to pivot toward own products: own-product revenue rose 25% in FY2021.
FY2022: margin repair, revenue down. Gross margin recovered to 48.6% as mix shifted toward own pharma products. Revenue still contracted 13% and profit stayed thin, with attributable NP of RMB 191M.
FY2023: kitchen-sink loss. Revenue grew 6% to RMB 4,068M and chemical-drug revenue rose 40.7%. Asset and goodwill impairments and an R&D expense ratio that rose 2.72 points to 7.68% nevertheless produced an attributable loss of RMB 551M and a consolidated loss of RMB 886M. The year reset the asset base: total assets fell about RMB 1.0bn.
FY2024: the inflection year. Revenue rose 26.8% to RMB 5,160M. Drivers were:
-
the first full year of NRDL-listed Ryzneuta and Hyruan ONE;
-
domestic own-product growth of 88% in H1 2024;
-
higher government grants and lower impairments.
Attributable NP returned to RMB 386M, OCF hit a five-year high of RMB 641M, and dividends resumed.
FY2025: quality over quantity. Revenue was flat (-0.5%). Pharma revenue grew 2.3% while vitamins fell about 15% in an oversupplied market. Gross margin dipped to 46.9% on lower vitamin pricing and own-product mix. Core profit improved materially: NP excluding non-recurring items rose 30.9%, helped by innovative-product revenue (Hyruan ONE +225%; Ryzneuta shipments +80%). Q3 2025 attributable NP nonetheless fell 25.6% YoY. The full-year result of RMB 402M was well below the roughly RMB 600M consensus at 3Q25 (Stockstar).
H1 2026: renewed pressure. Revenue fell 6.4% and attributable NP fell 32.5%. Causes were:
-
respiratory TCM declines;
-
the Ryzneuta NRDL price reduction;
-
higher R&D expense (ACT001 Phase III, F-652);
-
FX losses;
-
lower government grants.
The quality of earnings improved (non-recurring items were small) and OCF more than doubled.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment / product line (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Pharma own products incl. imported (CNY Mn) | 1,627 | — | 2,432 | 3,664 | 3,837 |
Total pharma business (CNY Mn) | — | — | — | 4,260 | 4,358 |
Vitamins B5 series (CNY Mn) | 470 | — | — | 718 | 613 |
API segment total, incl. vitamins (CNY Mn) | 1,062 | — | — | — | — |
Pharma promotion services (CNY Mn) | 907 | — | — | — | — |
Group revenue (CNY Mn) | 4,409 | 3,837 | 4,068 | 5,160 | 5,133 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGross margin (%)
| Gross margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Pharma own products incl. imported (%) | 61.84 | — | 57.05 | 52.46 | 51.88 |
Vitamins (%) | — | — | — | — | 41.66 |
API segment, incl. vitamins (%) | 44.54 | — | — | — | — |
Pharma services (%) | 25.62 | — | — | — | — |
Group gross margin (%) | 41.47 | 48.63 | 47.84 | 47.42 | 46.88 |
Share of group revenue (%)
| Share of group revenue (%) | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Pharma own products (%) | 36.90 | 59.79 | 71.02 | 74.75 |
Vitamins (%) | 10.66 | — | 13.92 | 11.95 |
Pharma services (%) | 20.57 | — | — | — |
YoY growth (%)
| YoY growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Pharma own products (%) | 25.08 | — | — | 50.66 | 4.71 |
Vitamins B5 (%) | -61.37 | — | — | — | -14.62 |
Group revenue (%) | -18.36 | -12.98 | 6.03 | 26.84 | -0.52 |
Revenue by Segment (Half-Yearly)
| H1 metric (CNY Mn) | H1 2025 | H1 2026 |
|---|---|---|
Group revenue | 2,635 | 2,468 |
Pharma total | 2,254 | 2,029 |
Pharma own products incl. imported | 1,990 | 1,837 |
Vitamins | 302 | — |
Group Entities
| Entity | Ownership | Role |
|---|---|---|
Hefei Yifan Biopharmaceutical (亿帆生物) | 100% | Pharma holding and commercial platform |
Hefei Yifan Pharmaceutical (合肥亿帆) | 100% | Pharma commercial |
Hefei Yifan Bio-Pharmaceutical Manufacturing (亿帆制药) | 100% | Formulation manufacturing; licensee of ACT001 |
Sichuan Defeng, Tianchang Yifan, Liaoning Yifan, Suzhou Yifan, Hunan Furong, Shenyang Aohua | 100% via Yifan Pharma | TCM and chemical formulation plants |
Sichuan Kaijing Pharma | 51% | Formulations |
Beijing Jisheng Kangtai | 71% | Pharma technology |
Yifan Youshengmeite | 51% | Pharma technology |
Hefei Xinzhu Biotech | 100% | Biologics/formulation; EU QP-audited; investment vehicle for the Gaorong fund |
Evive Biotech Ltd. (Cayman) | 66.92% via HK Yifan | Large-molecule innovation; subsidiaries in Shanghai, Beijing, HK, US (Delaware), Singapore and Ireland |
Hangzhou Xinfu Technology, Anqing Xinfu, Chongqing Xinfu, Huzhou Xinfu New Materials, Zhejiang Yiben Tech | 100% | Vitamin B5, pro-B5 and polymers (PVB, PBS) |
Yifan International (HK), NovoTek Pharmaceuticals (HK), Feisuo Medicine and Tek Medicine (Italy), SciGen Pte Ltd (Singapore), YF Pharmaceutical International (US), YiFan Pharma (US) | 100% | International registration and commercial platform |
Yifan Pharmaceutical Research Institute (Beijing) | 100% | Central R&D |
Bioton S.A. (Warsaw Stock Exchange) | 31.65%, indirect | Associate; Polish insulin producer |
ITabMed Co., Ltd. | 15.64% via Evive | Minority biotech investment |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 4,409 | 3,837 | 4,068 | 5,160 | 5,133 |
Gross profit (CNY Mn) | 1,828 | 1,866 | 1,946 | 2,447 | 2,406 |
Operating profit (CNY Mn) | — | — | — | — | 429 |
Total profit before tax (CNY Mn) | — | — | — | — | 424 |
Net profit, consolidated (CNY Mn) | — | 127 | -886 | 324 | 373 |
Net profit attributable to parent (CNY Mn) | 278 | 191 | -551 | 386 | 402 |
Net profit attributable, excl. non-recurring items (CNY Mn) | 220 | 90 | -533 | 248 | 325 |
Minority interests (CNY Mn) | — | -64 | -335 | -62 | -29 |
Basic EPS (MYR Bn) | 0.23 | 0.16 | -0.45 | 0.32 | 0.33 |
Diluted EPS (MYR Bn) | — | 0.15 | -0.45 | 0.32 | 0.33 |
Dividend per share (MYR Bn) | 0 | 0 | 0 | 0.20 | 0.10 |
Margin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 41.47 | 48.63 | 47.84 | 47.42 | 46.88 |
Operating margin (%) | — | — | — | — | 8.35 |
Net margin, attributable (%) | 6.31 | 4.98 | -13.55 | 7.48 | 7.83 |
Net margin, consolidated (%) | 5.49 | 3.31 | -21.77 | 6.27 | 7.28 |
Revenue growth YoY (%) | -18.36 | -12.98 | 6.03 | 26.84 | -0.52 |
Attributable NP growth YoY (%) | -71.25 | -31.22 | -388.19 | 170.04 | 4.16 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 11,833 | 12,544 | 11,500 | 12,286 | 12,845 |
Total liabilities (CNY Mn) | 3,298 | — | 3,245 | 3,859 | 4,134 |
Equity attributable to parent (CNY Mn) | — | 8,812 | 8,276 | 8,522 | 8,835 |
Total equity (CNY Mn) | 8,535 | — | — | — | 8,711 |
Cash and cash equivalents at year end (CNY Mn) | — | — | — | — | 664 |
Goodwill (CNY Mn) | 2,738 | — | — | — | — |
Liabilities-to-assets ratio (%) | 27.87 | — | 28.22 | 31.41 | 32.18 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 301 | 472 | 349 | 641 | 458 |
Investing cash flow (CNY Mn) | -508 | — | — | — | -454 |
Financing cash flow (CNY Mn) | 222 | — | — | — | -114 |
Dividends declared for the year (CNY Mn) | 0 | 0 | 0 | 243 | 122 |
OCF / attributable NP (x) | 1.08 | 2.47 | — | 1.66 | 1.14 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, weighted average (%) | 3.28 | 2.20 | -6.35 | 4.48 | 4.63 |
ROIC (%) | 2.44 | — | — | — | — |
ROA (%) | — | — | — | — | 2.97 |
Total asset turnover (x) | 0.37 | — | — | — | 0.41 |
Receivables turnover (x) | 4.23 | — | — | — | — |
Inventory turnover (x) | 4.14 | — | — | — | — |
Cash Flow
| Metric (CNY Mn) | Q1 2025 | Q1 2026 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Revenue | 1,327 | 1,256 | 2,635 | 2,468 |
Attributable NP | 153 | 107 | 304 | 205 |
Attributable NP excl. non-recurring | 95 | 104 | 237 | 203 |
Operating cash flow | 182 | 285 | 286 | 594 |
Geographic Indicator Details
| Geographic indicator | Detail | Source |
|---|---|---|
Overseas formulation revenue | "Record high" in H1 2024; an H1 2025 figure exists in the investor-relations Q&A but was truncated in the source | STCN Aug 2024; Stockstar |
Vitamin B5 export share | About 70% sold to Europe, the Americas and other regions | FY2025 annual report abstract |
Markets with product sales | More than 50 countries or regions cumulatively | FY2025 annual report abstract |
Ryzneuta approvals | 31 (Aug 2024), 36 (end-2025), 39 (mid-2026) | STCN; FY2025 annual report; Tianfeng |
Ryzneuta US end-price | USD 4,600 per vial, about 14x the China price | ifeng; Fxbaogao investor-relations minutes |
Acrotech US order | Binding 2025 purchase orders above 40k vials (half-year); volume and sales targets raised in May 2025 | CLS, Aug 2025 |
Geographic revenue (CNY Mn) | FY2023 | FY2024 |
Segment Overview
| Segment | China | US | Europe | South-East Asia / Singapore | Latin America | Other |
|---|---|---|---|---|---|---|
Ryzneuta (biologics) | Core volume via partners; NRDL | Acrotech license; launched Jul 2025 | EU approved Mar 2024; partners in Germany, France, Italy, Poland, UK | Registrations | Brazil approved | Russia, Bangladesh and the Balkans (Albania, Kosovo, Montenegro) |
Chemical drugs | VBP-exposed; specialty niches | US subsidiaries | Italy (Feisuo/Tek); amikacin to the EU | Singapore (SciGen); norepinephrine approved | Diazoxide to Brazil | Oxytocin nasal spray to Russia |
TCM | Core market | — | — | Singapore exports of four products | Brazil APL trial (Huangdai) | — |
Vitamin B5 | About 30% | Major export destination | Major export destination | — | — | — |
Share Price History
| Date | Price (MYR Bn) | Context |
|---|---|---|
30 Sep 2025 | 13.74 | Northbound snapshot |
31 Dec 2025 | 11.84 | — |
31 Mar 2026 | 12.56 | — |
30 Jun 2026 | 9.35 | — |
30 Jul 2026 | 10.23 | Market cap RMB 12.44bn; float market cap RMB 8.61bn |
31 Jul 2026 | 10.27 | Latest captured |
Valuation Multiples
| Multiple | Yifan | Peer reference (Shenwan chemical-API median) |
|---|---|---|
P/E (TTM) | 35.0x | 52–53x |
P/E historical percentile | About 5–6% (near the low of its own history; minimum 31.98x) | — |
P/B | 1.42x | 2.5x |
Dividend yield | About 0.98% | About 1.05% |
EV/Sales (c) | About 2.4x (market cap / FY2025 revenue; excludes net debt, which was not captured) | — |
EV/EBITDA | Not publicly disclosed (EBITDA not captured) | — |
Analyst Ratings & Targets
| Broker | Date | Rating | Forecasts |
|---|---|---|---|
Tianfeng Securities (Yang Song, Cao Wenqing) | Sep 2026 | Buy (maintained) | Revenue: RMB 5,189M (2026E), 5,555M (2027E), 5,940M (2028E). Attributable NP: RMB 431M, 533M, 659M. |
Zheshang Securities | 10 Sep 2026 | Upgraded to Buy | Not captured |
Guosheng Securities | 2024 | Buy | FY2024–26 NP of RMB 574M / 727M / 943M (since overtaken by actuals: FY2024 RMB 386M, FY2025 RMB 402M) |
Consensus (Stockstar, 3Q25) | Oct 2025 | — | FY2025 NP of RMB 600M and EPS of RMB 0.49 (actual RMB 402M and RMB 0.33, a miss) |
Forecast metric (Tianfeng, Sep 2026) | FY2026 | FY2027 | FY2028 |
Revenue (CNY Mn) | 5,189 | 5,555 | 5,940 |
Attributable NP (CNY Mn) | 431 | 533 | 659 |
Analyst Conclusions
Guidance and consensus
The company gives no numerical guidance. Tianfeng's September 2026 model implies:
-
FY2026 revenue of about RMB 5.19bn, roughly flat (+1.1%);
-
FY2026 attributable NP of RMB 431M (+7%);
-
an acceleration to RMB 659M by FY2028, a 2025–2028 CAGR of about 18%.
Hitting FY2026 requires a strong H2: H1 NP was only RMB 205M, so H2 needs about RMB 226M, against RMB 98M in H2 2025.
Bull case
-
Ryzneuta becomes a genuine global product. Shipments rose more than 80% in 2025 and more than 50% in H1 2026, approvals reached 39 countries, and NCCN Category 1 status plus a USD 4,600 US price give it a long runway. A second EMA-approved site removes the supply bottleneck.
-
ACT001 delivers a first-in-indication approval. Phase III is 76% enrolled with BTD, which could deliver a 2027–2028 launch into an unmet SCLC brain-metastases niche for an upfront of only RMB 100M.
-
Valuation is near historical lows. P/E of about 35x sits at the 5th–6th percentile of its own history and P/B of 1.4x against a sector of 2.5x. Improving core profit (+31% in FY2025) and strong OCF in H1 2026 suggest de-risked downside.
Bear case
-
The domestic base is eroding faster than innovation grows. Own products fell 7.7% in H1 2026, respiratory TCM declined steeply, and the Ryzneuta NRDL price cut means two innovative products grew revenue only 12.5% despite 40% higher shipments.
-
The profit record is undermined by misses. FY2025 NP was a third below consensus, Q1 and H1 2026 NP fell about 30%, and grant dependence and FX make earnings noisy. Single-digit ROE does not justify a premium.
-
Governance and balance-sheet overhangs persist. Founder control comes with pledges and personal guarantees, cash covered only a third of current liabilities, and the FY2023 impairment history and capitalised R&D (64% in FY2021) leave further write-down risk.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q3 2026 report (revenue trajectory; H2 NP recovery) | Late Oct 2026 |
| ACT001 Phase III enrolment completion and topline timing | 2026–2027 |
| Ryzneuta new-country approvals (4 pending) and EU partner launches | Rolling |
| Acrotech US volumes and 2026 order book | Rolling |
| F-652 aGVHD Phase II first-patient-in; N-3C01 Phase I start | 2026–2027 |
| Compound Yinhua Jiedu paediatric influenza approval after CDE supplements | 2026–2027 |
| NRDL renewal and price outcomes (Ryzneuta, Hyruan ONE) | Late 2026 |
| Vitamin B5 price trend | Monthly |
| Controlling-shareholder pledge ratio | Rolling |
| FY2026 dividend and Quality and Return Dual Improvement execution | Apr 2027 |
Analyst verdict
Yifan Pharmaceutical is a company whose strategic narrative has outrun its income statement. The narrative itself is credible.
Few Chinese mid-caps have taken a self-developed biologic through FDA, EMA and NMPA approval, won NCCN Category 1 guideline status, and secured a US price roughly fourteen times the domestic one. Ryzneuta's shipment growth (more than 80% in 2025 and more than 50% in H1 2026) and its expanding registration map show the asset is real.
The ACT001 in-licence is a capital-efficient bet on a late-stage, breakthrough-designated oncology asset. Hyruan ONE adds a fast-growing orthopaedic leg.
The reported numbers are less convincing:
-
Five-year revenue CAGR is under 4%.
-
ROE has not exceeded 5% since 2020.
-
Profit has missed consensus repeatedly.
-
H1 2026 attributable NP fell by a third.
The domestic generics and TCM base, still about three-quarters of revenue, faces structural policy pressure. Innovative-product revenue is not yet large enough to offset that pressure, particularly after the NRDL price reset on Ryzneuta. Vitamin B5 adds cyclical noise. Governance features also warrant a discount: concentrated founder control, share pledges and reliance on the chairman's personal guarantees.
At about 35x trailing earnings and 1.4x book, near the bottom of its own valuation history, the market is already pricing considerable scepticism.
The verdict is a qualified, catalyst-dependent positive (Hold with upside bias). Upgrading conviction requires evidence on three fronts:
-
Q3/Q4 2026 results showing the H2 profit recovery that sell-side estimates assume.
-
A clean ACT001 Phase III readout path.
-
Disclosure showing overseas Ryzneuta turning profitable at the segment level.
Failure on the first would argue that the domestic erosion is structural and that the multiple should compress further. Success on all three would support re-rating toward sector multiples.
DATA GAPS & DISCREPANCIES LOG
Entity mismatch: no exact "Jiangsu Yifan Biotechnology Co., Ltd." was found; the dossier profiles Yifan Pharmaceutical (002019.SZ). CB Insights' "based in Jiangsu" conflicts with the company's Zhejiang registration and Anhui operations.
FY2025 consolidated net profit: Pharnexcloud gives RMB 373.45M; cfi.cn gives RMB 431.75M. RMB 373.45M was adopted because it reconciles with RMB 402.02M attributable less RMB 28.57M minorities.
cfi.cn paid-in capital: of RMB 1,036.68M conflicts with the 1,216.39M-share dividend base and EPS; the latter was adopted.
FY2023 own-product revenue: RMB 2,010M (Guosheng, likely domestic only) versus RMB 2,432M (Lixinger, including overseas).
-
Not captured or not publicly disclosed in the sources reviewed:
-
EBITDA and D&A, capex, FCF, interest-bearing debt split, net debt and working capital;
-
domestic/overseas revenue tables, full top-10 shareholders and executive compensation;
-
ISIN, auditor fee and employee trend;
-
FY2022–FY2024 R&D totals;
-
competitor benchmark figures and end-market sizes.
-
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Notes |
|---|---|---|
Cheng Xianfeng (程先锋) | Chairman, legal representative, controlling shareholder and actual controller; also holds a senior management role | Founder of the Hefei Yifan business; personally guarantees up to RMB 3.0bn of company bank debt at no fee |
Feng Deqi (冯德崎) | Director; board secretary; senior executive | Investor-relations and governance lead |
Zhou Benyu (周本余) | Director | A related natural person of Cheng Xianfeng (recused on related-party items) |
Zeng Yuhong (曾玉红) | Independent director | — |
Liu Meijuan (刘梅娟) | Independent director | — |
Sixth director | Not identified in the sources reviewed | — |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Cheng Xianfeng | Chairman (and executive) | — |
Zhang Dawei (张大巍) | Head of accounting (CFO-equivalent, 主管会计工作负责人) | In role since at least FY2023 |
Wang Kai (王恺) | Head of accounting department | — |
Feng Deqi | Board secretary | — |
Simon Li, M.D., Ph.D. | CEO and CMO, Evive Biotech (as of Nov 2022) | — |
Yu Haixia (喻海霞) | Former head of accounting (FY2021–FY2022) | Succeeded by Zhang Dawei |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Cheng Xianfeng | Largest holder. 10.06% of floating shares at end-2021; total stake not captured. | CS.com.cn (FY2021) |
Hong Kong Securities Clearing (Northbound) | 28.68M shares (about 2.36% of total) | Q1 2026 top-10 floating holders |
China Innovative Drug ETF (159992) | 11.10M shares | Q1 2026 |
Northbound holding value | RMB 216M, 2.74% of float | Lixinger, 30 Jun 2026 |
Shareholder accounts | About 46,600 (Jun 2026) | Sina Finance |
Share pledges | Pledged shares equal 12.32% of top-10 holdings (Jul 2026); controlling-shareholder pledges extended Feb 2026 | Lixinger; Q1 2026 report |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Product | Relative positioning |
|---|---|---|---|
Long-acting G-CSF (China) | Jiangsu Hengrui Medicine | Pegfilgrastim (艾多), mecapegfilgrastim | Market leaders with scale advantage; Ryzneuta differentiates on non-PEG design and head-to-head data |
Long-acting G-CSF (China) | CSPC Pharmaceutical | PEG-rhG-CSF (津优力) | Incumbent first mover |
Long-acting G-CSF (China) | Qilu Pharmaceutical | Pegfilgrastim | Low-cost competitor |
Long-acting G-CSF (US) | Amgen | Neulasta® / Onpro | Originator; dominant |
Long-acting G-CSF (US) | Coherus BioSciences, Sandoz, Fresenius Kabi, Biocon/Viatris | Pegfilgrastim biosimilars | Price pressure on US end-prices |
Long-acting G-CSF (US) | Assertio (formerly Spectrum) | Rolvedon® (eflapegrastim) | Novel competitor and closest analogue |
HA viscosupplement (China) | Sanofi (Synvisc-One); Bloomage; domestic HA makers | Single-injection or multi-dose HA | Hyruan ONE competes on the single-injection, six-month profile |
Haemato-oncology / APL | Arsenic trioxide producers | ATO injections | Compound Huangdai is the oral alternative |
Paediatric / respiratory TCM | Yiling Pharmaceutical; China Resources Sanjiu; Jiangsu Kanion | Respiratory TCM | Category under policy pressure |
Vitamin B5 | DSM-Firmenich; Brother Enterprise (兄弟科技); Shandong Xinfa (新发药业); Huaheng Biotech (HMO / amino acids) | D-Ca pantothenate | Yifan claims leading global share; commodity pricing |
Specialty injectables export | Zhejiang Huahai, Hainan Poly, Nanjing King-friend | EU/US injectables | Overlaps with the international generics platform |
Competitor Detail
| Metric | Yifan Pharmaceutical |
|---|---|
Revenue | 5,133 |
Revenue growth (%) | -0.5 |
Gross margin (%) | 46.9 |
Attributable net margin (%) | 7.8 |
R&D intensity (%) | 6.9 |
Recent Developments
--



